Troutman Pepper Advises Digital Pathology Company Proscia in $23M Series B Funding

PHILADELPHIA – Troutman Pepper client Proscia®, a leading provider of digital and computational pathology solutions, has secured $23 million in Series B funding led by Scale Venture Partners, with participation from Hitachi Ventures. The investment brings Proscia’s total funding to $35 million. Read a company press release about the financing.

Proscia aims to perfect cancer diagnosis with intelligent software that changes the way the world practices pathology. The company is accelerating the transformation to digital pathology with its Concentriq® software platform, which centers around high-resolution images of tissue biopsies, as the new standard of care.

Troutman Pepper’s Thomas Dwyer, Kenneth Minturn, Ravenna Neville, Michael Crumbock and Morgan Klinzing counseled Proscia in the Series B financing. The firm has advised Proscia since 2017, including in its $8.3 million round of Series A financing from a group of East and West Coast venture capital firms in September 2018.

The firm regularly advises startup, emerging growth and venture capital clients through every stage of their life cycle. Industries served span software, hardware and other high-technology, life sciences, biotechnology, pharmaceuticals and medical devices, financial technology, healthcare, consumer products, food and beverage, media and telecommunications products and services, and many others.

Visit seed.troutman.com to learn more about Troutman Pepper’s program for Startup and Early-Stage Entrepreneurial Development (SEED).

About Troutman Pepper 
Troutman Pepper is a national law firm known for its higher commitment to client care. With more than 1,100 attorneys in 23 U.S. cities, the firm partners with clients across every industry sector to help them achieve their business goals. Read more about the firm’s litigation, transactional, and regulatory practices at troutman.com.